|
Bay Area Tumor Institute CCOP
|
5U10CA045461-20
|
$521,201
|
$10,424
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Proteosome Inhibition Therapy for Hematologic Malignancy
|
5K23CA113775-04
|
$134,015
|
$67,008
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Improving the Efficacy of Dendritic Cell Vaccines
|
3P01CA084512-07S1
|
$200,000
|
$40,000
|
Banchereau, Jacques
|
BAYLOR RESEARCH INSTITUTE
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-26
|
$430,954
|
$4,310
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-11
|
$130,866
|
$3,926
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Effects of mTOR inhibitors on multiple myeloma tumors
|
5K01CA111623-05
|
$149,580
|
$149,580
|
Frost, Patrick
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
Regulation of c-myc translation by hnRNP A1: role in multiple myeloma tumor respo
|
1R01CA132778-01A2
|
$275,837
|
$275,837
|
GERA, JOSEPH
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
Sensitivity Multiple Myeloma Cells to mTOR Inhibitors
|
5R01CA111448-05
|
$188,765
|
$188,765
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
Use of CCI-779 in multiple myeloma
|
5R21CA121464-02
|
$319,950
|
$319,950
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
Energy Balance, IGF Dysregulation and Multiple Myeloma
|
5K07CA115687-04
|
$140,130
|
$140,130
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Carle Cancer Center Community Clinical Oncology Program
|
5U10CA035195-26
|
$841,092
|
$8,411
|
ROWLAND, KENDRITH
|
CARLE CLINIC ASSOCIATION, P C
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-35
|
$417,370
|
$12,521
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cedar Rapids Oncology Project
|
5U10CA052352-20
|
$446,062
|
$4,461
|
WIESENFELD, MARTIN
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
A Novel Antibody Therapeutic for Multiple Myeloma
|
5R44CA105840-03
|
$466,655
|
$466,655
|
CHINTALACHARUVU, KOTESWARA
|
CHIMERIC TECHNOLOGIES, INC.
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-23
|
$1,282,700
|
$25,654
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-22
|
$332,211
|
$13,288
|
MORTIMER, JOANNE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Southwest Oncology Group
|
5U10CA004919-50
|
$195,727
|
$7,829
|
BUDD, G
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
CCOP: Colorado Cancer Research Program
|
5U10CA067753-14
|
$1,053,364
|
$10,534
|
Pajon, Eduardo
|
COLORADO CANCER RESEARCH PROGRAM, INC.
|
|
Determinants and risks of use and overuse of expensive oncology drugs
|
5R01CA134964-02
|
$259,686
|
$51,937
|
HERSHMAN, DAWN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Columbus Community Clinical Oncology Program
|
5U10CA035261-26
|
$930,000
|
$9,300
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Targeted Therapy of B-cell Malignancies
|
3P01CA103985-04S1
|
$519,832
|
$51,983
|
GOLDENBERG, DAVID
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
2R01CA050947-17A1
|
$287,403
|
$287,403
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
SPORE in Myeloma
|
5P50CA100707-07
|
$2,300,000
|
$2,300,000
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S1
|
$124,531
|
$1,245
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S2
|
$100,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-45S5
|
$143,383
|
$1,434
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA006516-45
|
$11,688,901
|
$116,889
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Selective Inhibition of HDAC6 in Cancer Therapy
|
5K08CA128972-02
|
$139,320
|
$139,320
|
BRADNER, JAMES
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer and Leukemia Group B
|
2U10CA032291-28
|
$413,820
|
$70,349
|
Burstein, Harold
|
DANA-FARBER CANCER INSTITUTE
|
|
CXCR4 regulation of tumor progression in Multiple Myeloma
|
5R01CA125690-02
|
$320,621
|
$320,621
|
Ghobrial, Irene
|
DANA-FARBER CANCER INSTITUTE
|
|
Targeting cell trafficking as a new therapeutic modality for Multiple Myeloma
|
5R01CA133799-02
|
$353,927
|
$353,927
|
Ghobrial, Irene
|
DANA-FARBER CANCER INSTITUTE
|
|
ECOG Statistical Office
|
5U10CA023318-33
|
$2,407,336
|
$72,220
|
GRAY, ROBERT
|
DANA-FARBER CANCER INSTITUTE
|
|
Differentiating Agents in Hematologic Malignancies
|
5R01CA042802-22
|
$333,828
|
$166,914
|
KUFE, DONALD
|
DANA-FARBER CANCER INSTITUTE
|
|
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma
|
5R01CA124929-02
|
$354,825
|
$354,825
|
MUNSHI, NIKHIL
|
DANA-FARBER CANCER INSTITUTE
|
|
MODIFICATIONS MATTER IN MCL1 TURNOVER AND CELL VIABILITY
|
5R01CA057359-17
|
$308,120
|
$154,060
|
Craig, Ruth
|
DARTMOUTH COLLEGE
|
|
Cancer Center Support Grant
|
2P30CA023108-31
|
$3,290,263
|
$164,513
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Cancer Center Support Grant
|
3P30CA023108-31S2
|
$87,459
|
$4,373
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Different active sites of the proteasome as drug targets in cancer
|
5R01CA124634-03
|
$273,429
|
$136,715
|
Kisselev, Alexei
|
DARTMOUTH COLLEGE
|
|
Dayton Clinical Oncology Program
|
2U10CA035090-27
|
$1,166,703
|
$11,667
|
GROSS, HOWARD
|
DAYTON CLINICAL ONCOLOGY PROGRAM
|
|
Central Illinois Community Clinical Oncology Program
|
5U10CA045807-24
|
$1,370,000
|
$13,700
|
WADE, JAMES
|
DECATUR MEMORIAL HOSPITAL
|
|
Eastern Cooperative Oncology Group Chair's Office
|
5U10CA086802-11
|
$655,420
|
$19,663
|
COMIS, ROBERT
|
DREXEL UNIVERSITY
|
|
Cancer and Leukemia Group B
|
2U10CA047577-22
|
$157,170
|
$26,719
|
CRAWFORD, JEFFREY
|
DUKE UNIVERSITY
|
|
Cancer and Leukemia Group B Statistical Center
|
2U10CA033601-30
|
$4,929,147
|
$837,955
|
GEORGE, STEPHEN
|
DUKE UNIVERSITY
|
|
Duluth Community Clinical Oncology Program
|
5U10CA035269-26
|
$747,046
|
$7,470
|
Nikcevich, Daniel
|
DULUTH CLINIC, LTD.
|
|
Proteosome inhibitor sensitivity in multiple myeloma: The role of ER stress
|
7R01CA127910-03
|
$121,568
|
$121,568
|
BOISE, LAWRENCE
|
EMORY UNIVERSITY
|
|
EORTC DATA CENTER
|
5U10CA011488-39
|
$809,323
|
$40,466
|
Sylvester, Richard
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
FASEB Conference-Hematological Malignancies
|
5R13CA117424-03
|
$9,710
|
$1,942
|
ZHANG, DONG-ER
|
FEDERATION OF AMER SOC FOR EXPER BIOLOGY
|
|
North Shore CCOP
|
5U10CA035279-26
|
$350,000
|
$10,500
|
VINCIGUERRA, VINCENT
|
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
|
|
Community Clinical Oncology Program: FL Pediatric CCOP
|
5U10CA035157-26
|
$382,772
|
$7,655
|
TALBERT, JAMES
|
FLORIDA ASSN OF PEDIATRIC TUMOR PROG
|
|
Eastern Cooperative Oncology Group
|
5U10CA027525-31
|
$453,259
|
$13,598
|
GOLDSTEIN, LORI
|
FOX CHASE CANCER CENTER
|
Total relevant funding to Multiple Myeloma for this search: $45,183,304
|